Trial Condition(s):

Multiple Sclerosis

Open, multicentric, prospective, quality of life Study in Multiple Sclerosis patients

Bayer Identifier:

14168

ClinicalTrials.gov Identifier:

NCT00928967

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To evaluate the evolution of the impact on daily life activities over the first 12 months following the introduction of interferon beta-1b treatment in patients presenting RRMS or patients at high risk of developing Multiple Sclerosis after a first clinical demyelinating event

Inclusion Criteria
:
 - Males or females aged 18 years or over, having received a confirmed diagnosis of RRMS as defined by the MacDonald or Poser criteria or after a first clinical demyelinating event suggestive of Multiple Sclerosis, and meeting the requirements of the study inclusion criteria
 - The choice of treatment must be clearly dissociated from the decision to include the patient in the study.
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
67
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, France

Status
Completed
 

Trial Design